Document Detail


Positive impact of blocking tumor necrosis factor alpha on the nutritional status in pediatric Crohn's disease patients.
MedLine Citation:
PMID:  18797887     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: TNFalpha seems to contribute to inflammation and malnutrition in Crohn's disease (CD) patients. In CD patients, the comparative effects on nutritional status of infliximab and traditional therapy have not yet been determined. The aim of our study was to assess the effects of infliximab as compared with those of standard therapy on nutritional status, disease activity, resting energy expenditure (REE), and food intake in CD children and adolescents. METHODS: From September 1999 to September 2005, all CD patients treated with infliximab (group A) were reviewed and matched with CD patients treated with traditional therapy (mesalazine and azathioprine) (group B). RESULTS: Fourteen CD patients from group A and 14 from group B were included; median interval before follow-up investigation was 10 months. Baseline and final values of weight, height, body mass index (BMI), pediatric CD activity index (pCDAI), REE, and food intake were studied. In treated patients, but not in control group, mean baseline weight (kg) and BMI values, 39.7 +/- 13.1 and 17.9 +/- 3.3, respectively, were significantly lower than their final values 42.6 +/- 13.2 and 18.9 +/- 3.1, and median pCDAI values 23.5 were significantly higher than their final values 10 (P < 0.05). Significant changes in height, REE, and food intake were not found in either group. CONCLUSIONS: In pediatric CD patients, infliximab seems to impact positively on the nutritional status as demonstrated by the improvement in weight and BMI, but not in linear growth; effects on nutritional status seem to be due to amelioration of disease activity, rather than to REE reduction or food intake increase.
Authors:
A Diamanti; M S Basso; M Gambarara; B Papadatou; F Bracci; C Noto; M Castro
Related Documents :
7702767 - National food contamination monitoring programmes-levels of mercury, lead and cadmium i...
18460617 - The correlation of potassium content and moisture in bovine liver samples analyzed for ...
11386727 - Induction of micronuclei in eel (anguilla anguilla l.) by heavy metals.
720297 - Interrelationships among zinc, copper, lead, and cadmium in food, feces, and organs of ...
18164027 - Regulation of gonad development and respiratory metabolism associated with food availab...
21898517 - The response of the frugivorous lion-tailed macaque (macaca silenus) to a period of fru...
Publication Detail:
Type:  Journal Article     Date:  2008-09-17
Journal Detail:
Title:  International journal of colorectal disease     Volume:  24     ISSN:  0179-1958     ISO Abbreviation:  Int J Colorectal Dis     Publication Date:  2009 Jan 
Date Detail:
Created Date:  2008-11-26     Completed Date:  2009-03-31     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8607899     Medline TA:  Int J Colorectal Dis     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  19-25     Citation Subset:  IM    
Affiliation:
Gastroenterology and Nutrition Unit, Bambino Gesù Children's Hospital, Piazza S. Onofrio, 4-00165, Rome, Italy. diamanti@opbg.net
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
Antibodies, Monoclonal / therapeutic use*
Azathioprine / therapeutic use
Body Height
Body Mass Index
Body Weight
Case-Control Studies
Child
Crohn Disease / drug therapy*
Eating
Energy Metabolism
Follow-Up Studies
Gastrointestinal Agents / therapeutic use*
Humans
Immunosuppressive Agents / therapeutic use
Mesalamine / therapeutic use
Nutritional Status*
Retrospective Studies
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Antibodies, Monoclonal; 0/Gastrointestinal Agents; 0/Immunosuppressive Agents; 0/Tumor Necrosis Factor-alpha; 0/infliximab; 446-86-6/Azathioprine; 89-57-6/Mesalamine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Multiple primary cancers in extracolonic sites with colorectal cancer.
Next Document:  Double primary malignancy in colorectal cancer patients--MSI is the useful marker for predicting dou...